(07 May 2021) – The European Commission is proposing a strategy on COVID-19 therapeutics to support the development and availability of COVID-19 therapeutics, including for the treatment of ‘long COVID’.
The strategy covers the full lifecycle of medicines: from research, development and manufacturing to procurement and deployment.
The European Medicines Agency has today started the rolling review of sotrovimab (VIR-7831), a monoclonal antibody developed for the treatment of COVID-19.
The Commission will draw up a portfolio of 10 potential COVID-19 therapeutics and by June 2021, identify the five most promising ones.
New authorisations, rolling reviews and joint procurement contracts will be up and running before the end of the year.